Researchers from the Massachusetts Institute of Technology (MIT) and Brigham and Women's Hospital showed that they can deliver the cancer drug cisplatin far more effectively and safely into the prostate tumor cells by using the encapsulation particles are activated only after reaching the target cell.
With this latest menggunakanpartikel scientists succeeded in eliminating tumor cells in mice by using just one third of conventional cisplatin required to achieve the same results. The results of this study is good news because it can reduce the side effects of cisplatin that can damage the kidneys and nervous system. Their study was led by Professor Stephen Lippard and has been published in the Proceedings of the National Academy of Sciences.
In 2008, researchers have found that the nanoparticles have a specific activity against cancer cell growth. Now these nanoparticles showed positive results of animal and most likely will have an impact similar to humans, but this is still to be evaluated further to be tested on humans.
Cisplatin or cis-diamindikloroplatina (II) (CDDP) is a type of complex compounds based on platinum metal (Pt) which is used as a drug for various cancers such as sarcomas, carcinomas (such as lung cancer and ovarian), lymphoma, and tumor cells. Cisplatin is the first member of the anti-cancer drugs are now also includes carboplatin and oxyplatin. The drug is used by doctors to treat cancer since the late 1970s due to its binding to cross-(cross-linking) that trigger cancer cell DNA is cell death. Although anti-cancer drug has side effects like kidney damage and nausea, half of cancer patients around the world who do chemotherapy using platinum-based drugs.
Another problem of the use of cisplatin is a very short life time in blood vessels. Only about 1% of the dose given to patients who mempu reach the target cell's DNA, and more than half excreted after 1 hour of treatment.
To prolong the circulation time of cisplatin, the researchers decided to wrap cisplatin with compounds that are hydrophobic (water-repellent). First, they modified the drug, which actually is hydrophilic (likes water), with two units heksanoat acid - an organic hydrophobic fragment. This may cause the encapsulated cisplatin to new and active when it has reached the target cell.
By using this approach, more drugs reach the tumor. The researchers found that these nanoparticles drugs circulate in the bloodstream for 24 hours, about 5 times longer than the drugs that are not encapsulated nanoparticles. They also found that fewer cisplatin accumulated in the kidney compared with conventional cisplatin. To help the nanoparticles reach the target, the researchers also coating with molecules that can bind to PSMA (prostate specific membrane antigen), a protein found in prostate tumor cells.
After showing increased lifetime drug nanoparticles in the blood, the researchers tested the effectiveness of the drug by treating mice that have been terimplan by human prostate tumors. They found that the size of cancer cells is reduced during the 30 days same as conventional medicine, but with a dose of only 30% of the usual.
Model drug nanoparticles can be applied easily to different kinds of anti-cancer drugs, and even more than one drug in a nanoparticle encapsulation. This drug also can be designed for other types of cancer besides prostate cancer, eg breast cancer by adjusting the target cells with receptors nanoparticles. Clinical testing in humans still requires several stages of experiments on animals and in the next three years of this invention is expected to be used by humans.
With this latest menggunakanpartikel scientists succeeded in eliminating tumor cells in mice by using just one third of conventional cisplatin required to achieve the same results. The results of this study is good news because it can reduce the side effects of cisplatin that can damage the kidneys and nervous system. Their study was led by Professor Stephen Lippard and has been published in the Proceedings of the National Academy of Sciences.
In 2008, researchers have found that the nanoparticles have a specific activity against cancer cell growth. Now these nanoparticles showed positive results of animal and most likely will have an impact similar to humans, but this is still to be evaluated further to be tested on humans.
Cisplatin or cis-diamindikloroplatina (II) (CDDP) is a type of complex compounds based on platinum metal (Pt) which is used as a drug for various cancers such as sarcomas, carcinomas (such as lung cancer and ovarian), lymphoma, and tumor cells. Cisplatin is the first member of the anti-cancer drugs are now also includes carboplatin and oxyplatin. The drug is used by doctors to treat cancer since the late 1970s due to its binding to cross-(cross-linking) that trigger cancer cell DNA is cell death. Although anti-cancer drug has side effects like kidney damage and nausea, half of cancer patients around the world who do chemotherapy using platinum-based drugs.
Another problem of the use of cisplatin is a very short life time in blood vessels. Only about 1% of the dose given to patients who mempu reach the target cell's DNA, and more than half excreted after 1 hour of treatment.
To prolong the circulation time of cisplatin, the researchers decided to wrap cisplatin with compounds that are hydrophobic (water-repellent). First, they modified the drug, which actually is hydrophilic (likes water), with two units heksanoat acid - an organic hydrophobic fragment. This may cause the encapsulated cisplatin to new and active when it has reached the target cell.
By using this approach, more drugs reach the tumor. The researchers found that these nanoparticles drugs circulate in the bloodstream for 24 hours, about 5 times longer than the drugs that are not encapsulated nanoparticles. They also found that fewer cisplatin accumulated in the kidney compared with conventional cisplatin. To help the nanoparticles reach the target, the researchers also coating with molecules that can bind to PSMA (prostate specific membrane antigen), a protein found in prostate tumor cells.
After showing increased lifetime drug nanoparticles in the blood, the researchers tested the effectiveness of the drug by treating mice that have been terimplan by human prostate tumors. They found that the size of cancer cells is reduced during the 30 days same as conventional medicine, but with a dose of only 30% of the usual.
Model drug nanoparticles can be applied easily to different kinds of anti-cancer drugs, and even more than one drug in a nanoparticle encapsulation. This drug also can be designed for other types of cancer besides prostate cancer, eg breast cancer by adjusting the target cells with receptors nanoparticles. Clinical testing in humans still requires several stages of experiments on animals and in the next three years of this invention is expected to be used by humans.
See other article Electric Bicycle by Ferrari
No comments:
Post a Comment